复星医药海外并购绩效分析及启示

发布时间：2017-12-27 00:29

本文关键词：复星医药海外并购绩效分析及启示　出处：《首都经济贸易大学》2017年硕士论文　论文类型：学位论文

【摘要】：进入21世纪以来,随着我国经济的快速增长,我国在全球经济中的地位逐渐提高,我国医药市场也成为仅次于美国的全球第二大医药市场。我国部分医药企业也逐步走向国际市场,开始在全球布局。最近几年,随着医药企业海外并购事件不断涌现,人们越来越关注海外并购能不能创造价值,以及跨国并购行为对企业经营绩效的影响。复星医药上市公司是通过投资并购发展起来的,其在成长过程中进行过多次国内外并购,对跨国并购积累了丰富经验。复星医药在2016年又耗费14亿美元收购印度GLAND公司。到底是什么原因在导致复星医药不停地进行海外并购。这背后到底蕴含着什么意义?并购是否能够给企业创造价值。本文以复星医药并购以色列Alma公司为案例进行分析,讨论并购的原因与整合效果。在此基础上,进一步分析这一成功案例能够为我国医药企业海外并购和战略整合提供相关经验和启示。
[Abstract]:Since entering twenty-first Century, with the rapid growth of China's economy, China's position in the global economy has been improving. China's pharmaceutical market has become the second largest pharmaceutical market in the world after the US. Some of the pharmaceutical enterprises in China are gradually moving towards the international market and began to be distributed globally. In recent years, with the emergence of overseas mergers and acquisitions of pharmaceutical companies, people pay more and more attention to whether overseas mergers and acquisitions can create value and the impact of cross-border M & A on business performance. Fosun Pharmaceutical Listed Company has been developed through investment merger and acquisition. It has made many domestic and foreign acquisitions during its growth, and has accumulated rich experience in cross-border mergers and acquisitions. In 2016, Fosun medicine spent 1 billion 400 million dollars to buy India GLAND. What is the reason for the continued overseas merger and acquisition of Fuxing medicine. What is the meaning behind this? Whether M & A can create value for the enterprise. This paper analyzes the case of the merger and acquisition of Alma in Israel, and discusses the reasons for the merger and the effect of the integration. On this basis, the further analysis of this successful case can provide some experience and inspiration for the overseas merger and strategic integration of Chinese pharmaceutical enterprises.
【学位授予单位】：首都经济贸易大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：F426.72;F271

【相似文献】